Increased Coffee Consumption Associated with Lower Risk of Liver Cancer

Reading time: 5 – 8 minutes

Here’s another reason to enjoy your coffee. A recent study in the July edition of the Journal Hepatology found a significant inverse association (meaning opposingly related; an increase in one variable results in a decrease in another) between coffee drinking and the risk of primary liver cancer [1]. The study also found that serum levels of an antioxidant enzyme, elevated in people with low coffee consumption, were associated with an increased risk of developing the disease.

Coffee
Creative Commons License photo credit: Marcelo Alves

Primary liver and bile duct cancers are the sixth most common cause of cancer death in men and the tenth most common cause of cancer death in women [2]. Hepatitis B and C viral infections have been identified as causative factors in greater than 75% of liver cancers worldwide [3]. Interestingly, incidence rates are low in most developed countries except for Japan, where coffee drinking is relatively uncommon. Several studies have also identified an inverse association between coffee consumption and serum levels of gamma-glutamyltransferase (GGT), an enzyme involved in glutathione metabolism [4-5]. Glutathione plays important roles in antioxidant defense, nutrient defense and regulation of a variety of cellular events [6].

Residents of Finland consume more coffee per capita than the Japanese, Americans, Italians and other Europeans. University of Helsinki researchers examined the associations between coffee consumption and serum GGT levels in 60,323 Finnish participants between the ages of 25 and 74 who were cancer-free at the beginning of the study.

Participants were mailed a questionnaire about their medical history, socioeconomic factors, smoking habits and dietary habits. A subset of participants (n = 37,842) had clinical data available, including alcohol consumption and serum levels of GGT. Study participants were divided into five categories based on their response to the question “How many cups of coffee do you drink daily?”:

  • Category 1:   0 — 1 cup
  • Category 2:   2 — 3 cups
  • Category 3:   4 — 5 cups
  • Category 4:   6 — 7 cups
  • Category 5:   8 or more cups per day

During a median follow-up period of 19.3 years, 128 participants were diagnosed with primary liver cancer.

incidence_vs_year_follow-up.pngThe researchers observed that the cumulative incidence curve of liver cancer decreased with increasing amounts of daily coffee consumption (graph). When the analysis was restricted to surveys from participants that had clinical data available, a statistically positive association was found between serum GGT level and liver cancer risk. Joint association of coffee consumption and serum GGT level with liver cancer showed that participants who drank 0 — 1 cups of coffee and were in the top 25% of subjects sampled with respect to serum GGT had about 9.2 times increased risk for liver cancer compared to participants who drank at least 6 cups of coffee daily and were in the bottom 75% of subjects sampled with respect to serum GGT.

The study results are consistent with two meta-analyses published last year demonstrating an inverse relation between coffee consumption and liver cancer [7-8]. While a previous investigation found an inverse association between coffee consumption and serum GGT level, this study is the first large prospective study to suggest that a high level of serum GGT is a risk factor for primary liver cancer. The authors discuss a mechanism for the association between coffee drinking and serum GGT on liver cancer risk [1]:

Several other putative mechanisms behind the association of coffee drinking and serum GGT on liver cancer risk have also been proposed. Coffee contains many compounds, such as chlorogenic acid, which may have the potential to influence glucose metabolism processes to prevent hyperglycemia, and consequently oxidative stress.

Indeed, chlorogenic acid, a chemical largely responsible for coffee’s bitterness, may also be responsible for coffee’s effect on serum GGT level and, ultimately, coffee’s health benefits.

More information and support for patients with “Liver cancer” can be found at Organized Wisdom and MDJunction. Additionally, the American Liver Foundation, the nation’s leading nonprofit organization promoting liver disease prevention and liver wellness, provides research, education and advocacy for those affected by liver-related diseases.

References

  1. Hu et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008 Jul;48(1):129-36. DOI: 10.1002/hep.22320
    View abstract

  2. A Snapshot of Liver and Bile Duct Cancers. American Cancer Society. Atlanta, Ga. 2007.
  3. Ferlay et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon, France: International Agency for Cancer Research; 2004.
  4. Casiglia et al. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993;9:293-297.
    View abstract
  5. Tanaka et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998;27:438-443.24.
    View abstract
  6. Wu et al. Glutathione metabolism and its implications for health. J Nutr. 2004 Mar;134(3):489-92.
    View abstract
  7. Larsson and Wolk. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007 May;132(5):1740-5. Epub 2007 Mar 24.
    View abstract
  8. Bravi et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology. 2007 Aug;46(2):430-5.
    View abstract
About the Author

Walter Jessen, Ph.D. is a Data Scientist, Digital Biologist, and Knowledge Engineer. His primary focus is to build and support expert systems, including AI (artificial intelligence) and user-generated platforms, and to identify and develop methods to capture, organize, integrate, and make accessible company knowledge. His research interests include disease biology modeling and biomarker identification. He is also a Principal at Highlight Health Media, which publishes Highlight HEALTH, and lead writer at Highlight HEALTH.